Cargando…

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene

BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) is used for the patients with EGFR-mutant lung cancer. Recently, phase III studies in the patients with EGFR-mutant demonstrated that EGFR-TKI mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Hisashi, Hayashi, Akihito, Morimoto, Takeshi, Taima, Kageaki, Tanaka, Yoshihito, Shimada, Michiko, Kurose, Akira, Takanashi, Shingo, Okumura, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515412/ https://www.ncbi.nlm.nih.gov/pubmed/23181703 http://dx.doi.org/10.1186/1471-2407-12-558

Ejemplares similares

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review
por: Tanaka, Hisashi, et al.
Publicado: (2013)

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016)

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Hisashi, et al.
Publicado: (2018)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus
por: Itoga, Masamichi, et al.
Publicado: (2015)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2017)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2021)

Emergency Radiotherapy for Spinal Cord Compression due to Bone Sarcoidosis
por: Tanaka, Yoshihito, et al.
Publicado: (2017)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene
por: Muscarella, Lucia Anna, et al.
Publicado: (2017)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers
por: Fukuyoshi, Y, et al.
Publicado: (2008)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
por: Shiratori, Toshihiro, et al.
Publicado: (2020)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung
por: Doval, DC, et al.
Publicado: (2015)

Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis
por: Wang, Ying, et al.
Publicado: (2014)

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer
por: Aydemirli, Mehtap Derya, et al.
Publicado: (2021)

EML4-ALK fusion gene in non-small cell lung cancer
por: Lei, Yu, et al.
Publicado: (2022)

Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
por: Zhao, Fengzhi, et al.
Publicado: (2015)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
por: Nakamura, Yume, et al.
Publicado: (2023)

Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
por: Liang, Wenhua, et al.
Publicado: (2016)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
por: Wen, Miaomiao, et al.
Publicado: (2016)

EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer
por: Jin, Guang, et al.
Publicado: (2012)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
por: Gococo-Benore, Denise A, et al.
Publicado: (2022)

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs
por: Cheon, So Yeong, et al.
Publicado: (2023)

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022)

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
por: Chung, Jon H., et al.
Publicado: (2014)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature
por: Han, Qianqian, et al.
Publicado: (2022)

Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation
por: Fujita, Kohei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rc5d7s4n65tn6j3vfeiinqemlq